STAT

Debate over whether to test a second Ebola vaccine turns acrimonious

An aggressive push to use a second experimental Ebola vaccine to try to help stop the outbreak in the Democratic Republic of the Congo may have backfired.
The DRC's health minister, Dr. Oly Ilunga Kalenga, seen visiting an Ebola treatment center in March.

An aggressive push to use a second experimental Ebola vaccine to try to help stop the nearly yearlong outbreak in the Democratic Republic of the Congo may have backfired, with the DRC’s health minister insisting the country will not allow use of the vaccine, made by pharmaceutical giant Johnson & Johnson.

The health minister, Dr. Oly Ilunga, had previously suggested a consortium made up of the London School of Hygiene and Tropical Medicine, Doctors Without Borders, and others might be permitted to conduct a clinical trial of J&J’s Ebola vaccine in the country, although not in the outbreak zone, where Merck’s experimental vaccine is being used.

Late last week he rescinded that option, saying the country would not approve a trial of another experimental vaccine during the ongoing outbreak, which has infected

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Arguments, A Merck Drug Approval, And More
U.S. Supreme Court justices focused on plaintiffs' right to sue the FDA to reinstate restrictions on a commonly used abortion pill, suggesting they are unlikely to restrict access.
STAT1 min read
STAT+: New Gene Therapy, To Be Priced At $4.25 Million, Has Already Transformed Children’s Lives
The world's most expensive treatment offers a near-cure for young children and redemption for its developer, but steep challenges still loom.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CAR-T Drugs For Myeloma, CVS Rebate Credits, And More
A FDA panel voted in favor of expanding use of CAR-T therapy in multiple myeloma, despite concerns about side effects.

Related Books & Audiobooks